Skip to content

Autologous Versus Synthetic Versus Biological Sling for Trans-obturator Correction of Urinary Stress Incontinence

A Comparison in Terms of Efficacy and Safety Among Three Different Materials for Trans-obturator Correction of Urinary Stress Incontinence: Autologous, Synthetic and Biological Sling

Status
UNKNOWN
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00744198
Enrollment
8
Registered
2008-08-29
Start date
2012-08-31
Completion date
Unknown
Last updated
2013-04-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stress Urinary Incontinence

Keywords

Autologous, Biological, Mesh, Polypropylene, Sling, Synthetic, Stress incontinence, Surgery, TOT, Treatment

Brief summary

The treatment of urinary stress incontinence with trans-obturator approach, know as transobturatory tape (TOT), is a largely used sling-adopting procedures. The efficacy and safety of this minimally invasive surgery have been demonstrated, also in comparison with similar procedures, i.e transvaginal tape (TVT). To date the results of TOT in terms of efficacy and safety described in literature mainly refer to procedure in which synthetic materials are used, whereas few data regarding the use of biological materials are available. Moreover, despite the well known benefits of the available synthetic and eterologue kit, their use may be limited by the high cost of these materials. At this proposal it can be suggested as alternative option the possibility to perform the procedure using an autologous tissue, i.e. rectus fascia, and reusable introductory needles. Based on these considerations the aim of this trial will be to compare autologous, synthetic and biological mesh for TOT in women with urinary stress incontinence.

Detailed description

Women with genuine stress urinary incontinence will be enrolled and randomized in three groups (arm 1, arm 2, arm 3). All patients will be treated with a transobturatory approach, in patients of arm 1 will be used an autologous tissue and reusable introductory needles, in patients of arm 2 will be used a synthetic kit whereas in arm 3 will be a biological kit . All eligible patients will undergo baseline assessment consisting of anthropometric, clinical, hormonal, urodynamic, and ultrasonographic evaluations. During the study, the surgical outcomes, the clinical subjective and objective efficacy data, and the adverse experiences will be evaluated in each patient. Data will be analyzed using the intention-to-treat principle and a P value of 0.05 or less will be considered significant.

Interventions

PROCEDUREAutologous transobturator tape procedure

A strip of rectus fascia is harvested. Small incision sites in the vagina and in the femoral/pelvic fold. Bilateral transobturator insertion of the autologous strip by means of reusable needles

PROCEDURESynthetic transobturator tape procedure

Small incision sites in the vagina and in the femoral/pelvic fold. Bilateral transobturator insertion of synthetic mesh by means of mono-use needles.

PROCEDUREBiological transobturator tape procedure

Small incision sites in the vagina and in the femoral/pelvic fold. Bilateral transobturator insertion of biological mesh by means of mono-use needle

Sponsors

University Magna Graecia
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* Genuine stress urinary incontinence by self report, examination and test * Urethral hypermobility * Eligible for all three surgical procedures * Ambulatory

Exclusion criteria

* Pregnancy * \<12 months post-partum * Systemic disease and/or drugs known to affect bladder function * Current chemotherapy or radiation therapy * Urethral diverticulum, augmentation cytoplasty, or artificial sphincter * Recent pelvic surgery * Severe genuine stress incontinence (loss of urine with minimal physical activity) with associated prolapse equal to or more than second degree * Previous pelvic or anti-incontinence surgery * History of severe abdominopelvic infections * Known extensive abdominopelvic adhesions * Detrusor instability and/or intrinsic sphincter dysfunction * Other gynaecologic pathologies (eg, fibroids, ovarian cysts) * BMI \>30

Design outcomes

Primary

MeasureTime frame
Cure rate12 months

Secondary

MeasureTime frame
Postoperative complications rate12 months
Failure rate12 months
Intra-operative complication rateone day
Quality of life12 months
Sexual function12 months
Recurrence rate12 months

Countries

Italy

Contacts

Primary ContactStefano Palomba, MD
stefanopalomba@tin.it

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026